Figure 8.

Effects of TM7SF3-siRNA on p21 mRNA levels. Nave HepG2 (a), MIN6 (b), U2-OS (c) and HepG2^sh–control or HepG2^sh-p53 cells (d) were transfected for 48 h (a, b and d) or for 6 days (c) with TM7SF3-siRNA or with a non-targeting sequence. Cells were treated with doxorubicin (2 μM for 24 h) (a and d); with Cytomix ‘1X' for the indicated periods of time (b); or were left untreated (c). RNA was extracted and quantified by qRT-PCR. Bar graphs are the mean±S.E.M. of at least three independent experiments. *P<0.05; **P<0.01; ***P<0.001 versus non-targeting siRNA assayed under the same conditions